# Consort 2010 Checklist Extension for Cluster Trials.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Section/Topic | Item No | Standard Checklist item | Extension for cluster designs | Page No \* |
| Title and abstract |  |
|  | 1a | Identification as a randomized trial in the title | Identification as a cluster randomized trial in the title | N/A |
| 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)[[1]](#endnote-1),[[2]](#endnote-2) | See table 2 | N/A based on journal’s abstract guideline. |
| Introduction |  |
| Background and objectives | 2a | Scientific background and explanation of rationale | Rationale for using a cluster design | 4-5 |
| 2b | Specific objectives or hypotheses | Whether objectives pertain to the the cluster level, the individual participant level or both | 5 |
| Methods |  |
| Trial design | 3a | Description of trial design (such as parallel, factorial) including allocation ratio | Definition of cluster and description of how the design features apply to the clusters | 28 |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons |  | **N/A** |
| Participants | 4a | Eligibility criteria for participants | Eligibility criteria for clusters  | 30-31 |
| 4b | Settings and locations where the data were collected |  | **29-30** |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | Whether interventions pertain to the cluster level, the individual participant level or both | 28-29 |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | Whether outcome measures pertain to the cluster level, the individual participant level or both | 33 |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons |  | **33** |
| Sample size | 7a | How sample size was determined | Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or *k*), and an indication of its uncertainty | 33-34 |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines |  | **N/A** |
| Randomisation: |  |
|  Sequence generation | 8a | Method used to generate the random allocation sequence |  | **N/A** |
| 8b | Type of randomisation; details of any restriction (such as blocking and block size) | Details of stratification or matching if used | N/A |
|  Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level or both | N/A |
|  Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | Replace by 10a, 10b and 10c |  |
|  | 10a |  | Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions | 28-30 |
|  | 10b |  | Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete enumeration, random sampling) | 28-30 |
|  | 10c |  | From whom consent was sought (representatives of the cluster, or individual cluster members, or both), and whether consent was sought before or after randomisation | 30-31 |
|  |  |  |  |  |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how |  | **30** |
| 11b | If relevant, description of the similarity of interventions |  | **28-29** |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | How clustering was taken into account | 34-35 |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses |  | **33-35** |
| Results |  |
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome | Figure 1 |
| 13b | For each group, losses and exclusions after randomisation, together with reasons | For each group, losses and exclusions for both clusters and individual cluster members | Figure 1 |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up |  | **6** |
| 14b | Why the trial ended or was stopped |  | **N/A** |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | Baseline characteristics for the individual and cluster levels as applicable for each group | Table 1 |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | For each group, number of clusters included in each analysis | Figure 1, Tables 2 and 3 |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or k) for each primary outcome | Table 2 |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended |  | Table 2, relative only |
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory |  | Table 3, Appendix 1-tables 12-15 |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms[[3]](#endnote-3)) |  | **N/A** |
| Discussion |  |
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses |  | **23-27** |
| Generalisability | 21 | Generalisability (external validity, applicability) of the trial findings | Generalisability to clusters and/or individual participants (as relevant) | 27-28 |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence |  | **14-15, 27-28** |
| Other information |  |  |
| Registration | 23 | Registration number and name of trial registry |  | **35** |
| Protocol | 24 | Where the full trial protocol can be accessed, if available |  | **28** |
| Funding | 25 | Sources of funding and other support (such as supply of drugs), role of funders |  | **36** |

1. [↑](#endnote-ref-1)
2. [↑](#endnote-ref-2)
3. [↑](#endnote-ref-3)